ライフサイエンスコーパス: neuropeptide Y

1 avage of a host protein-derived peptide (pro-neuropeptide Y).

2 OM), vasoactive intestinal peptide (VIP), or neuropeptide Y.

3 es such as stromal cell-derived factor-1 and neuropeptide Y.

4 decarboxylase-67 (GAD67), somatostatin, and neuropeptide Y.

5 ell type-specific distribution of endogenous neuropeptide Y.

6 e pool neurons that already express GABA and neuropeptide Y.

7 amage, and compensatory changes in EAAT3 and neuropeptide Y.

8 estrogen receptor-alpha colocalization with neuropeptide Y.

9 es and peptides such as leptin, ghrelin, and neuropeptide Y.

10 abundant levels of tyrosine hydroxylase and neuropeptide Y.

11 ferent orexigenic molecules: AgRP; GABA; and neuropeptide Y.

12 lar (3V) infusions of the orexigenic peptide neuropeptide Y 3-36 in awake, freely moving rats and det

13 dNPF is an ortholog of the mammalian neuropeptide Y, a highly conserved neuromodulator that s

14 rocessed for immunocytochemistry for SST and neuropeptide Y, a neuropeptide partially coexpressed in

15 In the current study, we found that neuropeptide Y, a protein produced by neurons, affected

16 Neurons coexpressing neuropeptide Y, agouti-related peptide, and GABA (NAG) p

17 Hypothalamic neuropeptide Y, agouti-related peptide, and proopiomelan

18 ial role of central alpha-klotho to modulate neuropeptide Y/agouti-related peptide (NPY/AgRP)-express

19 icted neuronal subsets (proopiomelanocortin, neuropeptide Y/agouti-related peptide, and steroidogenic

20 ng hormone neurons but has limited effect on neuropeptide Y/agouti-related protein and proopiomelanoc

21 ons of the arcuate nucleus, specifically the neuropeptide Y/agouti-related protein neurons and the do

22 of tanycytes ex vivo depolarized orexigenic (neuropeptide Y/agouti-related protein; NPY/AgRP) and ano

23 ances the activity of agouti-related protein/neuropeptide Y (AgRP/NPY)-expressing neurons but induces

24 ls containing parvalbumin, somatostatin, and neuropeptide Y also show unique topographical distributi

25 approaches we show this plasticity requires neuropeptide Y, an adrenal cotransmitter and the activat

26 f sympathetic nerves and tissue abundance of neuropeptide-Y, an indicator of sympathetic nerve activi

27 (-/-) mice, and other transcripts, including neuropeptide Y and activating transcription factor-3, ar

28 reduced appetite-stimulating neuropeptides, neuropeptide Y and Agouti-related peptide.

29 d by arcuate nucleus neurons that co-express neuropeptide Y and agouti-related protein (NPY/AgRP neur

30 d food intake, body weight, and hypothalamic neuropeptide Y and Agouti-related protein mRNA expressio

31 nduced hepatic FGF21, which caused increased neuropeptide Y and agouti-related protein mRNAs in the h

32 he regulation of social behavior (especially neuropeptide Y and corticotropin-releasing factor) are m

33 disorder are enhanced hippocampal levels of neuropeptide Y and EAAT3 and increased calpain proteolys

34 at co-express agouti-related protein (AgRP), neuropeptide Y and gamma-aminobutyric acid (GABA) are kn

35 he receptor binding motifs of members of the neuropeptide Y and glucagon families modulate receptor a

36 control animals and had lower expression of neuropeptide Y and higher expression of proopiomelanocor

37 In the arcuate nucleus, both Neuropeptide Y and proopiomelanocortin cells expressed t

38 f brainstem and hypothalamic neurons express neuropeptide Y and proopiomelanocortin in the arcuate nu

39 of GABAergic GAD67+ interneurons expressing neuropeptide Y and somatostatin are reduced in the hippo

40 2.2 is not required for the specification of neuropeptide Y and vasoactive intestinal polypeptide, in

41 coneogenic enzymes and elevated hypothalamic neuropeptide-Y and agouti-related protein mRNA levels.

42 calized with cholinergic starburst ACs, NPY (neuropeptide Y)- and EBF1 (early B-cell factor 1)-positi

43 n analogue of the C-terminal pentapeptide of neuropeptide Y, and a neuropeptide FF analogue) were sub

44 othalamic neuropeptides proopiomelanocortin, neuropeptide Y, and agouti-related peptide in T1D mice.

45 Ivy cells express nitric oxide synthase, neuropeptide Y, and high levels of GABA(A) receptor alph

46 against calbindin, parvalbumin, calretinin, neuropeptide Y, and somatostatin, and the number of inte

47 -regulating proteins agouti-related peptide, neuropeptide Y, and uncoupling protein 2 in the hypothal

48 hich express the orexigenic neuronal marker, Neuropeptide-Y, and respond to fasting and leptin-induce

49 Agouti-related peptide (AGRP) and Neuropeptide Y are potent orexigens and are coexpressed

50 ress characteristic combinations of GABA and neuropeptide Y as cotransmitters and Lim1,2 and Nurr1 tr

51 the insulin promotor (Ins2) were stained for neuropeptide Y before, during, and after virally induced

52 s that synthesize agouti-related peptide and neuropeptide Y but inhibited anorexigenic neurons that s

53 e BBB-impermeable neuropeptides dalargin and neuropeptide Y chemically conjugated with FC5-Fc fusion

54 .93]) after stressful training; lower plasma neuropeptide Y concentration after stressful training (d

55 ures were heart rate, breathing rate, plasma neuropeptide Y concentration, score on the Response to S

56 Neuropeptide Y-containing interneurons in the dentate hi

57 rvated by inhibitory interneurons expressing neuropeptide Y::Cre (NPY(+)) in the dorsal spinal cord.

58 eurons that are defined by the expression of neuropeptide Y::Cre (NPY::Cre) act to gate mechanical it

59 Neuropeptide Y detection was performed.

60 cholecystokinin, but inhibited by orexigenic neuropeptide Y, dynorphin and met-enkephalin, consistent

61 the mammalian target of rapamycin pathway in neuropeptide-Y-ergic neurons of the arcuate nucleus, and

62 A significant reduction of calbindin-, NPY (neuropeptide Y)-expressing, and cholinergic interneurons

63 ic inhibitory circuit involving a variety of neuropeptide Y-expressing interneurons.

64 endrites, whereas nitric oxide synthase- and neuropeptide Y-expressing ivy cells provided synaptic an

65 In addition, we found neuropeptide Y expression almost exclusively in those GI

66 Surprisingly, hypothalamic neuropeptide Y expression was completely suppressed, sug

67 nders to two model peptides, angiotensin and neuropeptide Y, following screening by solution phage pa

68 g mice showed increased levels of C-terminal neuropeptide Y fragments and increased neurogenesis.

69 single nucleotide polymorphism (SNP) in the neuropeptide Y gene has been associated with elevated se

70 bilaterian neuropeptide receptors, including neuropeptide Y, gonadotropin inhibitory hormone (GnIH),

71 Both serotonin (5-HT) and neuropeptide Y have been shown to affect a variety of ma

72 essing Drosophila neuropeptide F (dNPF), the neuropeptide Y homolog, strongly correlates with food-od

73 leasing short neuropeptide F, the Drosophila neuropeptide Y homolog.

74 used immunohistochemistry for calretinin and neuropeptide Y in 24 age- and gender-matched patients wi

75 nthesize gamma-amino-butyric acid (GABA) and neuropeptide Y in adult mice leads to starvation within

76 d release of the orexigenic neurotransmitter neuropeptide Y in response to glucose.

77 ons expressing parvalbumin, somatostatin and neuropeptide Y in the dentate gyrus, reduced aberrant ne

78 pro-opiomelanocortin/agouti-related peptide/neuropeptide Y in the hypothalamus of the rats.

79 rvating (calretinin(+), somatostatin(+), and neuropeptide Y(+)) interneurons.

80 Numbers of neuropeptide Y-IR neurons were not affected.

81 osal plexus and was expressed exclusively by neuropeptide Y-IR neurons.

82 Neuropeptide Y is a key peptide affecting adiposity and

83 neuropeptides such as ghrelin, orexin A and neuropeptide Y is also discussed.

84 Multiple peptide systems, including neuropeptide Y, leptin, ghrelin, and others, are involve

85 P, corticotropin releasing factor (CRF), and neuropeptide Y levels in adult male Long-Evans rats defe

86 n and attraction is thought to depend on the neuropeptide Y-like receptor NPR-1, because solitary and

87 ting cells and identified neurons expressing neuropeptide Y-like short neuropeptide F (sNPF).

88 -expressing interneurons and initiation of a neuropeptide-y-like signaling axis that promotes elevate

89 cystokinin/CB(1) cannabinoid receptor(+) and neuropeptide Y(+) local-circuit interneurons upon SAVA m

90 f both Lifeact-GFP and the SG marker protein neuropeptide Y-mCherry reveals that SGs actively translo

91 Aptamer-modified microelectrodes for Neuropeptide Y measurement by electrochemical impedance

92 and inhibited by orexigenic neuromodulators neuropeptide Y, met-enkephalin, dynorphin and the catech

93 tissue weight, fecal output, arcuate nucleus neuropeptide Y mRNA expression, plasma corticosterone, a

94 ng hormone but surprisingly has no effect on neuropeptide Y mRNA, a neuropeptide previously shown to

95 Neuropeptide Y neurons have been shown to be particularl

96 s, stimulation of the agouti-related protein/neuropeptide Y neurons, and activation of the hypothalam

97 activated L-type Ca(2+) currents in arcuate neuropeptide Y neurons.

98 lly significant difference in the density of neuropeptide Y+ neurons between subjects with autism and

99 coordinated action of Caenorhabditis elegans neuropeptide Y/neuropeptide F and serotonin that could a

100 , we identified the evolutionary ortholog of neuropeptide Y/neuropeptide F in the nematode Caenorhabd

101 n, corticotropin releasing hormone, galanin, neuropeptide Y, neurotensin, preproenkephalin and tachyk

102 in, dynorphin) and brain antistress systems (neuropeptide Y, nociceptin [orphanin FQ]) in drug depend

103 r, metabotropic glutamate receptors-2 mGlu2, neuropeptide-Y NPY, and mineralocorticoid receptors MR).

104 l stages influences IGL neurons that express neuropeptide Y (NPY) (hereafter, IGL(NPY) neurons), guid

105 d identify the vasoconstrictive mechanism as Neuropeptide Y (NPY) acting on Y1 receptors.

106 e truncated cleaved form of neurotransmitter neuropeptide Y (NPY) actively promotes a breach of BM va

107 Neuropeptide Y (NPY) administration into the basolateral

108 Bioconjugates containing the neuropeptide Y (NPY) analogue [F(7),P(34)]-NPY as target

109 In lean mice, the adipokine leptin inhibits neuropeptide Y (NPY) and agouti-related peptide (AgRP) n

110 bits neurotransmission in neurons expressing neuropeptide Y (NPY) and agouti-related peptide (AgRP) v

111 Neuropeptide Y (NPY) and Agouti-related protein (AgRP),

112 Endogenous neuropeptide Y (NPY) and corticotrophin-releasing factor

113 s that regulate stress and reward, including neuropeptide Y (NPY) and corticotropin-releasing factor

114 s, including somatostatin (SST), tachykinin, neuropeptide Y (NPY) and cortistatin, in a pattern remin

115 was developed for the sensitive detection of neuropeptide Y (NPY) and employed in the analysis of NPY

116 c), containing pro-opoiomelanocortin (POMC), neuropeptide Y (NPY) and growth hormone releasing hormon

117 Neuropeptide Y (NPY) and its receptors (especially Y1, Y

118 up-regulating specific target genes, such as neuropeptide Y (NPY) and its Y1 and Y5 receptors (Y5Rs).

119 Neuropeptide Y (NPY) and NPY receptors represent a highl

120 rgetic state, circulating steroids, and both neuropeptide Y (NPY) and orexin (OX) immunoreactivity.

121 and modulation of neurological signals, with Neuropeptide Y (NPY) and Orexin A (OXA) offering diagnos

122 Neuropeptide Y (NPY) and pancreatic polypeptide (PP) con

123 the lateral hypothalamus (LH) together with neuropeptide Y (NPY) and proopiomelanocortin (POMC) neur

124 the total number of interneurons expressing neuropeptide Y (NPY) and vasoactive intestinal polypepti

125 Other peptides such as neuropeptide Y (NPY) are synthesized throughout the brai

126 Orexin A (OXA) and neuropeptide Y (NPY) are two hypothalamic neuropeptides

127 sh, and here we report the identification of neuropeptide Y (NPY) as both necessary for normal daytim

128 in a structural model of the peptide hormone neuropeptide Y (NPY) bound to its human G-protein-couple

129 in the basolateral amygdaloid complex (BLA), neuropeptide Y (NPY) buffers against protracted anxiety

130 e ontogeny of proopiomelanocortin (POMC) and neuropeptide Y (NPY) cell populations, which exert oppos

131 stimulatory connections onto the neighboring neuropeptide Y (NPY) cells.

132 The hypothalamic neuropeptide Y (NPY) circuitry is a key regulator of fee

133 strongly implicated hindbrain catecholamine/neuropeptide Y (NPY) coexpressing neurons as key mediato

134 ression of agouti-related protein (Agrp) and neuropeptide Y (Npy) coincide with the cyclic changes in

135 c (tg) mice affected primarily the levels of neuropeptide Y (NPY) compared with other neuropeptides.

136 subpopulation of CA1 interneurons expressing neuropeptide Y (NPY) contributes prominently to this dyn

137 Neuropeptide Y (NPY) counters stress and is involved in

138 we show that the claims of Zhou et al. that neuropeptide Y (NPY) diplotype-predicted expression is c

139 The DMH contains neurons expressing Neuropeptide Y (NPY) during specific physiological condi

140 Endogenous neuropeptide Y (NPY) exerts long-lasting spinal inhibito

141 s glucocorticoids have pronounced effects on neuropeptide Y (NPY) expression and as NPY neurons proje

142 We found that neuropeptide Y (NPY) expression identifies a class of GA

143 pproach in mice of both sexes, we found that neuropeptide Y (NPY) expression identifies a major class

144 gered molecular plasticity including ectopic neuropeptide Y (NPY) expression in granule cells, but wi

145 element binding) binding protein (CBP), and neuropeptide Y (NPY) expression in the amygdaloid brain

146 Because neuropeptide Y (NPY) expression is strongly induced in D

147 pression of vGLUT1 but not vGAT, and reduced Neuropeptide Y (NPY) expression.

148 nes and their cognate receptors belonging to neuropeptide Y (NPY) family mediate diverse biological f

149 ucagon-like peptide-1 (GLP-1), glucagon, and neuropeptide Y (NPY) from circumvallate papillae of Tas1

150 Neuropeptide Y (NPY) gene expression in the hippocampal

151 anxiety and other psychiatric disorders and neuropeptide Y (NPY) has emerged as a key component of a

152 Neuropeptide Y (NPY) has robust anxiolytic properties an

153 SIGNIFICANCE STATEMENT: Neuropeptide Y (NPY) has robust anxiolytic properties, a

154 While recent animal studies of neuropeptide Y (NPY) have suggested a facilitator role f

155 Previous studies have suggested that neuropeptide Y (NPY) in the dorsomedial hypothalamus (DM

156 The expression of the orexigenic neuropeptide Y (NPY) in the hypothalamus to the low lept

157 ted by changes in tonic inhibition of SNA by neuropeptide Y (NPY) in the paraventricular nucleus (PVN

158 ted with reduced tonic inhibition of LSNA by neuropeptide Y (NPY) in the PVN.

159 However, the specific role of neuropeptide Y (NPY) in this process has not been system

160 Neuropeptide Y (NPY) interacts with the Y(1) receptor, N

161 ic inputs to the two populations of striatal neuropeptide Y (NPY) interneurons, plateau low threshold

162 Neuropeptide Y (NPY) is a 36-amino acid peptide circulat

163 Neuropeptide Y (NPY) is a 36-amino-acid peptide transmit

164 Neuropeptide Y (NPY) is a hypothalamic neuropeptide that

165 Neuropeptide Y (NPY) is a peptide known for its anti-anx

166 Neuropeptide Y (NPY) is a putative endogenous anxiolytic

167 Neuropeptide Y (NPY) is a well-established orexigenic pe

168 Neuropeptide Y (NPY) is an important modulatory neuropep

169 Neuropeptide Y (NPY) is anxiolytic and its release is in

170 EMENT Within the basolateral amygdala (BLA), neuropeptide Y (NPY) is associated with buffering the ne

171 Neuropeptide Y (NPY) is induced in peripheral tissues su

172 Neuropeptide Y (NPY) is one of the major neuropeptides p

173 Neuropeptide Y (NPY) is one of the most abundant protein

174 Neuropeptide Y (NPY) is one of the most widespread neuro

175 cord following inflammation or nerve injury, neuropeptide Y (NPY) is poised to regulate the transmiss

176 ported that the sympathetic neurotransmitter neuropeptide Y (NPY) is potently angiogenic, primarily t

177 Neuropeptide Y (NPY) is produced in the intergeniculate

178 Here we show that Neuropeptide Y (NPY) is uniquely required for the long-l

179 evious observations that fluorescent-labeled neuropeptide Y (NPY) is usually released within 200 ms a

180 Among them, neuropeptide Y (NPY) is well known to promote aversive m

181 Neuropeptide Y (NPY) is widely expressed in the central

182 ICV TTR decreased neuropeptide Y (NPY) levels in the DMH and the paraventr

183 understand whether genetic variation at the Neuropeptide Y (NPY) locus governs secretion and stress

184 Neuropeptide Y (NPY) mediates stress-induced obesity in

185 cordings were made from GFP (Renilla)-tagged neuropeptide Y (NPY) neurons from the arcuate nucleus of

186 Neuropeptide Y (NPY) neurons in both the arcuate nucleus

187 nhibitory effect of Dyn-A on arcuate nucleus neuropeptide Y (NPY) neurons mediated by both 1 and (kap

188 In contrast, kisspeptin inhibits orexigenic neuropeptide Y (NPY) neurons through an indirect mechani

189 The DMH contains orexigenic neuropeptide Y (NPY) neurons, but the role of these neur

190 he purpose of this study was to characterize neuropeptide Y (NPY) overflow and metabolism from isolat

191 Recent studies suggest that human neuropeptide Y (NPY) plays a prominent role in managemen

192 Neuropeptide Y (NPY) produces anxiolytic effects in rode

193 nt protein is expressed under control of the neuropeptide Y (NPY) promoter and striatal NPY-expressin

194 a green fluorescent protein (GFP) under the neuropeptide Y (NPY) promoter.

195 Within the family of neuropeptide Y (NPY) receptors, the Y(4) receptor (Y(4)R

196 he autonomic nervous system and hypothalamic neuropeptide Y (NPY) release during fasting regulates he

197 Neuropeptide Y (NPY) signaling in the CNS was modulated

198 Neuropeptide Y (NPY) signaling via limbic NPY1 and 2 rec

199 In the current study, we found that neuropeptide Y (NPY) suppressed monocyte recruitment to

200 on requires simultaneous withdrawal of tonic neuropeptide Y (NPY) sympathoinhibition.

201 It has been speculated this alters neuropeptide Y (NPY) synthesis, trafficking, or secretio

202 Functional genetic variation of neuropeptide Y (NPY) was recently identified as a source

203 We found that Neuropeptide Y (NPY) was significantly down-regulated in

204 We applied this BiFC system to study example neuropeptide Y (NPY) Y1 receptor dimers.

205 d the role of alpha-adrenergic receptor- and neuropeptide Y (NPY) Y1 receptor-mediated vasoconstricti

206 Activation of neuropeptide Y (NPY) Y1 receptors (Y1r) in the rat basol

207 ations of GABAergic interneurones expressing neuropeptide Y (NPY)(+), parvalbumin (PV)(+) and tyrosin

208 neurons [gamma-aminobutyric acid (GABA)(+), neuropeptide Y (NPY)(+), proopiomelanocortin (POMC)(+),

209 Neuropeptide Y (NPY), a 36 aa peptide, regulates stress

210 Neuropeptide Y (NPY), a brain neuromodulator that has be

211 study, we identified increased expression of neuropeptide Y (NPY), a pleiotropic growth factor which

212 have studied the subcellular distribution of neuropeptide Y (NPY), a prototypical and broadly express

213 Neuropeptide Y (NPY), a stress modulatory transmitter, i

214 Our previous studies have identified neuropeptide Y (NPY), a sympathetic neurotransmitter exp

215 In birds, CART inhibits food intake, whereas neuropeptide Y (NPY), a well-known orexigenic peptide, s

216 ry indicate that cortical astrocytes contain neuropeptide Y (NPY), a widespread neuronal transmitter.

217 from chemotherapy-induced cell death, while neuropeptide Y (NPY), acting via its Y2 receptor (Y2R),

218 c neuron markers proopiomelanocortin (POMC), neuropeptide Y (NPY), agouti-related peptide (AGRP), som

219 ment, hypothalamic mRNA expression levels of neuropeptide Y (NPY), agouti-related protein (AGRP), pro

220 We studied the actions of neuropeptide Y (NPY), an abundant neocortical neuropepti

221 se changes are regulated postsynaptically by neuropeptide Y (NPY), an adrenal cotransmitter.

222 creased mRNA levels of hypothalamic GHS-R1a, neuropeptide Y (NPY), and agouti-related protein (AgRP),

223 (CB), parvalbumin (PV), calretinin (CR) and neuropeptide Y (NPY), and somatostatin (SOM) and glial f

224 Over 80% of these neuron also express neuropeptide Y (NPY), and this coexpression is maintaine

225 augments the SCN clock-resetting effects of neuropeptide Y (NPY), another neurochemical correlate of

226 ctor 3 (ATF3), the neuropeptides galanin and neuropeptide Y (NPY), brain-derived neurotrophic factor

227 -melanocyte-stimulating hormone (alpha-MSH), neuropeptide Y (NPY), glutamate, and GABA from first-ord

228 ), galanin, gastrin-releasing peptide (GRP), neuropeptide Y (NPY), nitric oxide synthase (NOS), serot

229 ed by either gamma-aminobutyric acid (GABA), neuropeptide Y (NPY), or beta-endorphin receptor blockad

230 vels of genes that regulate appetite, namely neuropeptide Y (NPY), pro-opiomelanocortin (POMC) and th

231 he well-characterized neuropeptides, such as neuropeptide Y (NPY), proopiomelanocortin (POMC), orexin

232 ent with PEDF + DHA induced transcription of neuropeptide y (npy), small proline-rich protein 1a (spr

233 xp4 expression induces ectopic expression of neuropeptide Y (Npy), which has been reported to be pres

234 effects were due to disrupted signalling of neuropeptide Y (NPY), which is known to mediate non-phot

235 ar interneurons of the dentate gyrus express neuropeptide Y (NPY), which modulates granule cell activ

236 One relevant target is neuropeptide Y (NPY), which regulates both stress and fo

237 l transduction pathway modulating release of neuropeptide Y (NPY), which stimulates OE stem cell acti

238 cell activation and promotes the activity of neuropeptide Y (NPY)- and agouti-related peptide (AgRP)-

239 nterneurons express col19a1 mRNA; subsets of neuropeptide Y (NPY)-, somatostatin (Som)-, and calbindi

240 rotein (Tg2576), Abeta causes dysfunction in neuropeptide Y (NPY)-expressing hypothalamic arcuate neu

241 e investigated the properties of neostriatal neuropeptide Y (NPY)-expressing interneurons in transgen

242 1 (GAD1) in either cholecystokinin (CCK)- or neuropeptide Y (NPY)-expressing interneurons.

243 (Cell 2019;176:687-701) determined that the neuropeptide Y (NPY)-like receptor 7 (NPYLR7) controls m

244 on, appeared to be precipitated by a loss of neuropeptide Y (NPY)-mediated local circuit inhibition a

245 ood attraction to aversion is regulated by a neuropeptide Y (NPY)-related brain signaling peptide.

246 We investigated a role for neuropeptide Y (NPY)-related signaling in long-term beha

247 ropeptides agouti-related protein (AgRP) and neuropeptide Y (NPY).

248 e-like ethanol drinking to study the role of neuropeptide Y (NPY).

249 r producing the neuropeptides enkephalin and neuropeptide Y (NPY).

250 III are GABAergic, and some of these express neuropeptide Y (NPY).

251 rsors and express neuronal proteins, such as neuropeptide Y (NPY).

252 F co-receptors GFRalpha1 and RET, as well as neuropeptide Y (NPY).

253 release of the anticonvulsant neuropeptide, neuropeptide Y (NPY).

254 expressing agouti-related peptide (AgRP) and neuropeptide Y (Npy).

255 n enzyme that truncates the neurotransmitter neuropeptide Y (NPY).

256 asting discharge rates of fluorescent-tagged neuropeptide-Y (NPY) (within 200 ms) and tissue plasmino

257 that express pro-opiomelanocortin (POMC) or neuropeptide-Y (NPY) and agouti-related protein (AgRP).

258 Orthologs of vertebrate neuropeptide-Y (NPY) known as neuropeptide-F (NPF) have

259 ridization to localize appetite-stimulating (neuropeptide Y, NPY; agouti-related protein, AGRP) and a

260 cal activity: the N-terminal region of human neuropeptide Y (NPY1-9, Tyr(1)-Pro(2)-Ser(3)-Lys(4)-Pro(

261 tostatin, vasoactive intestinal polypeptide, neuropeptide Y, or cholecystokinin (antigens commonly co

262 Furthermore, loss of calbindin, neuropeptide Y, parvalbumin, and GAD65-positive interneu

263 The neuropeptide Y pathway acts together with SRB-13 to anta

264 Moreover, an increased number of neuropeptide Y-positive interneurons in the DG correlate

265 h changes in parvalbumin-, somatostatin- and neuropeptide Y-positive interneurons.

266 e submucosal plexus, DOReGFP was detected in neuropeptide Y-positive secretomotor and vasodilator neu

267 Loss of neuropeptide Y prevents a fasting-induced increase in ep

268 pressing green fluorescent protein under the neuropeptide Y promoter, we find that, across all layers

269 tance P, calcitonin gene-related peptide, or neuropeptide Y protein expression in DRGs and spinal cor

270 Lower mRNA levels of neuropeptide Y receptor 1 (NPY1R) and NPY5R but not NPY

271 Infusion of a specific neuropeptide Y receptor 5 agonist into the PVN consequen

272 -related behavior, while pretreatment with a neuropeptide Y receptor 5 antagonist prevented the anxio

273 e proteins that is upregulated by OXT is the neuropeptide Y receptor 5.

274 boratory-derived, mutation controlled by the neuropeptide Y receptor homolog npr-1 can affect dauer l

275 The neuropeptide Y receptor homolog, NPR-1, and an inhibitor

276 multiple signaling molecules, including the neuropeptide Y receptor NPR-1 and the calcineurin subuni

277 The neuropeptide receptor neuropeptide Y receptor type 1 (Npy1r) amalgamated multi

278 Here, the conformational dynamics of the neuropeptide Y receptor type 2 (Y2R) during activation w

279 on and this effect was blocked by a specific neuropeptide Y receptor Y1 (NPY1R) antagonist.

280 ion, although this was blocked by a specific neuropeptide Y receptor Y1 receptor antagonist, suggesti

281 ne, which encodes a homolog of the mammalian neuropeptide Y receptor.

282 coupled receptor (GPCR) related to mammalian neuropeptide Y receptors, functions to suppress innate i

283 uantification of neuronal glucocorticoid and neuropeptide Y receptors.

284 Y1 receptor (Y1R) and Y5 receptor (Y5R) for neuropeptide Y share similar actions in the regulation o

285 ive deficits, as well as endocannabinoid and neuropeptide Y system alterations and altered circadian

286 The neuropeptide Y system consists of several neuropeptides

287 ic, hypothalamic-pituitary-adrenal axis, and neuropeptide Y systems.

288 er was monitored by observing DCV-associated neuropeptide Y tagged with a fluorescent protein.

289 receptor systems (bombesin, neurotensin, and neuropeptide-Y) that offer high potential in the field o

290 d tumor necrosis factor, whereas addition of neuropeptide Y to wild-type macrophages attenuates the r

291 s-associated increase of immunoreactivity of neuropeptide Y, tyrosine hydroxylase, and somatostatin.

292 In contrast, interneurons containing neuropeptide Y, vasoactive intestinal peptide, or the 5-

293 hypothalamic expression of the orexic gene, neuropeptide Y, was lower and expression of the anorexic

294 (AgRP) neurons (which also release AgRP and neuropeptide Y), we generated mice with an AgRP neuron-s

295 ropeptide F (sNPF), an ortholog of mammalian neuropeptide Y, which we show here is a direct target of

296 Neuropeptide Y Y(1) receptors (Y(1)R) have been found to

297 The results suggest that neuropeptide Y Y1R differentially expressed in the limbi

298 Some in the trafficking of G protein-coupled neuropeptide Y Y2 receptor (NPY(2)R) and serotonin 5-hyd

299 The role of neuropeptide Y Y2 receptor (Y2R) in human diseases such

300 ereomeric mixture) is a potent and selective neuropeptide Y Y4 receptor agonist.